Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

NSCLC, metastatic 2

4059 - Phase 2 Trial (BRF113928) of Dabrafenib (D) Plus Trametinib (T) in Patients (pts) With Previously Untreated BRAF V600E–Mutant Metastatic Non-Small Cell Lung Cancer (NSCLC)


11 Sep 2017


NSCLC, metastatic 2


David Planchard


Annals of Oncology (2017) 28 (suppl_5): v605-v649. 10.1093/annonc/mdx440


D. Planchard1, E.F. Smit2, H.J.M. Groen3, J. Mazieres4, B. Besse5, Å. Helland6, V. Giannone7, A. D'Amelio7, P. Zhang7, B. Mookerjee7, B. Johnson8

Author affiliations

  • 1 Department Of Medical Oncology, Gustave Roussy, 94805 - Villejuif/FR
  • 2 Thoracic Oncology, Vrije Universiteit VU Medical Centre, Amsterdam/NL
  • 3 Department Of Pulmonary Diseases, University of Groningen and University Medical Center Groningen, Groningen/NL
  • 4 Thoracic Oncology Department, Rangueil-Larrey Hospital, Paul Sabatier University, Toulouse/FR
  • 5 Department Of Medicine, Gustave Roussy, Villejuif/FR
  • 6 Cancer Genetics, Oslo University Hospital, Oslo/NO
  • 7 Medical Oncology, Novartis Pharmaceuticals Corporation, East Hanover/US
  • 8 Department Of Medical Oncology, Dana-Farber Cancer Institute, Boston/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4059


BRAF V600E mutation occurs in ≈ 1%-2% of lung adenocarcinomas. D+T showed substantial clinical activity in pts with previously treated BRAF V600E–mutant metastatic NSCLC, with an investigator (INV)-assessed confirmed overall response rate (ORR) of 67%, median progression-free survival (PFS) of 10.2 mo, and median overall survival (OS) of 18.2 mo. We report results of D+T therapy in treatment-naive pts with BRAF V600E–mutant metastatic NSCLC.


In this cohort of the phase 2 BRF113928 trial (NCT01336634), pts with BRAF V600E–mutant metastatic NSCLC without prior systemic therapy for metastatic disease received D 150 mg twice daily + T 2 mg once daily. The primary endpoint was INV-assessed ORR. Secondary endpoints included duration of response (DOR), PFS, OS, and safety.


36 pts received D+T as first-line therapy. At the data cutoff (28 Apr 2017), median follow-up was 15.9 mo, and 11 pts (31%) remained on study treatment. Median age was 67 y (range, 44-91 y); most pts were female (61%), white (83%), and current/former smokers (72%). The INV-assessed confirmed ORR was 64% (95% CI, 46%-79%), with 2 complete responses (6%) and 21 partial responses (58%). Four pts (11%) had stable disease ≥ 12 wk (disease control rate, 75% [95% CI, 58%-88%]). These results were supported by independent review committee assessment. INV-assessed median DOR was 10.4 mo (95% CI, 8.3-17.9 mo), and median PFS was 10.9 mo (95% CI, 7.0-16.6 mo; 24 pts progressed or died). Median OS was 24.6 mo (95% CI, 12.3 mo-not estimable; 17 pts died). All pts experienced ≥ 1 adverse event (AE), and 69% had ≥ 1 grade 3/4 AE. Serious AEs (SAEs) in > 2 pts included alanine aminotransferase increase (14%), pyrexia (11%), aspartate aminotransferase increase (8%), and ejection fraction decrease (8%). One pt died due to an SAE (cardiorespiratory arrest) that was determined to be unrelated to study treatment.


D+T demonstrated clinically meaningful antitumor activity and a manageable safety profile in pts with previously untreated BRAF V600E–mutant metastatic NSCLC, supporting recent approval by the European Commission and US FDA.

Clinical trial identification

Clinical trial ID: NIH ClinicalTrials.gov NCT01336634 First received April 7, 2011

Legal entity responsible for the study

Novartis Pharmaceuticals Corporation


Novartis Pharmaceuticals Corporation


D. Planchard: Consultancy/Advisory Role: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, MSD, Pfizer, Roche, Novartis, Chugai. E.F. Smit: Consulting/Advisory Role: Lillly Research Funding: Boehringer Ingelheiim, Bayer, Roche/Genentech, AstraZeneca. H.J.M. Groen: Consulting/Advisory Role: Pfizer, Novartis, Bristol-Meyers Squibb, MSD Oncology, Lilly, Abbvie, Roche/Genentech Research Funding: Lilly, Roche. J. Mazieres: Research Funding: Roche, Bristol-Myers Squibb. B. Besse: Research Funding: AstraZeneca, Roche/Genentech, Pfizer, Boehringer Ingelheim, Lilly, Servier, Onxeo, Bristol-Myers Squibb, Ose Pharma, Inivata, Novartis Travel/Accommodations/Expenses: Roche, Pfizer, Bristol Myers Squibb/Medarex, Novartis, Pierre Fabre. V. Giannone, P. Zhang: Employment: Novartis. A. D\'Amelio: Employment: Novartis Stock or Other Ownership: Novartis, GlaxoSmithKline. B. Mookerjee: Employment: Novartis, GlaxoSmithKline Stock or Other Ownership: Novartis, GlaxoSmithKline, Incyte, AstraZeneca. B. Johnson: Stock or Other Ownership: KEW Group Honoraria: Chugai Consulting/Advisory Role: Novartis, Eli Lilly, Amgen, Boehringer Ingelheim, AstraZeneca, Clovis, Genentech, Merck Grant: Toshiba Post Marketing Royalties (DFCI): EGFR Mutation Testing. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.